Cover Image
市場調查報告書

醣生物學:全球診斷藥及治療藥市場

Glycobiology: Global Markets for Diagnostics and Therapeutics

出版商 BCC Research 商品編碼 371847
出版日期 內容資訊 英文 137 Pages
訂單完成後即時交付
價格
Back to Top
醣生物學:全球診斷藥及治療藥市場 Glycobiology: Global Markets for Diagnostics and Therapeutics
出版日期: 2016年09月26日 內容資訊: 英文 137 Pages
簡介

全球醣生物學市場預計從2016年的246億美元到2021年達到501億美元。2016∼2021年的年複合成長率預計為15.3%。

本報告提供全球醣生物學的診斷藥及治療藥市場相關調查,市場概要與趨勢,至2021年的預測,專利分析,及產業的主要參與企業簡介彙整。

第1章 簡介

第2章 摘要

第3章 醣生物學市場簡介

  • 概要
    • 聚醣的重要性
    • 聚醣的功能和其生物學的重要性
    • 醣生物學研究工具
    • 聚醣結構分析
    • 醣生物學研究一部分的醣質學
    • 聚醣和複合甜性的化學合成和酵素合成
    • 醣生物學研究的生物資訊學和資料庫資源

第4章 醣生物學治療藥市場

  • 概要
  • 醣生物學治療藥的子分類
  • 小分子藥物成分的聚醣
  • 流感病毒神經胺糖酸酶的小分子抑制劑
  • 治療的糖蛋白質
  • 對代謝性疾病的聚醣治療方法 其他

第5章 醣生物學診斷藥市場

  • 概要
  • 市場現狀

第6章 醣生物學研究開發所採用的工具和試劑市場

  • 概要
    • 分析與層析法技術
    • 聚醣陣列
    • 凝集素陣列
    • 醣生物學套件
    • 醣生物學研究的試劑
    • 甜性
    • 醣生物學研究開發的工具及試劑市場

第7章 醣生物學市場專利分析

  • 概要

第8章 市場摘要

第9章 主要企業概要

  • BIOMARIN PHARMACEUTICAL INC.
  • GLYCOMIMETICS
  • GLYCAN BIOSCIENCES LLC
  • GLYCOSENSORS AND DIAGNOSTICS LLC
  • GLYCOTEST INC.

第10章 本報告參照的企業名錄

  • 企業名錄

圖表

目錄
Product Code: BIO153A

REPORT HIGHLIGHTS

The global market for glycobiology will grow from nearly $24.6 billion in 2016 to nearly $50.1 billion by 2021 with a compound annual growth rate (CAGR) of 15.3% for the period of 2016-2021.

This report provides:

  • An overview of the global markets for glycobiology diagnostics and therapeutics.
  • Analyses of market trends, with data from 2015, 2016, and projections of CAGRs through 2021.
  • Analyses of current trends, products, evolving technologies and new glycobiology related platforms in different clinical areas including oncology, immunology, cardiovascular, infectious diseases and neurodegeneration.
  • A look at new tools for synthesizing, modifying and studying oligosaccharides and glycoconjugates.
  • Evaluation of promising candidates for carbohydrate-based diagnostics, drugs and vaccines.
  • Insight into how glycobiology offers enormous untapped potential in the discovery of new therapeutics derived from saccharides or other molecules which target the biosynthesis and function of saccharides.
  • Profiles of major players in the industry.

SCOPE AND FORMAT

This report presents current and important business tools to evaluate new commercial opportunities in glycobiology diagnostics, therapeutics and research tools market. The geographic scope of this study covers companies in the U.S. and worldwide. This market is complex and consists of number of different segments, each affected differently by scientific and technological development. The report identifies the main positive and negative factors in each segment and forecasts further trends, products and assay developments.

ANALYST'S CREDENTIALS

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology and industrial assay development and drug manufacturing. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • SCOPE AND FORMAT
  • METHODOLOGY AND INFORMATION SOURCES
  • INTENDED AUDIENCE
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR GLYCOBIOLOGY, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR GLYCOBIOLOGY, BY SEGMENT, 2014-2021 ($ MILLIONS)

CHAPTER 3 - INTRODUCTION TO GLYCOBIOLOGY MARKET

  • OVERVIEW
    • GLYCOBIOLOGY DEFINITION
      • TABLE 1: CLASSIFICATION OF CARBOHYDRATES
    • SIGNIFICANCE OF GLYCAN
      • FIGURE 1: SCHEMATIC PRESENTATION OF O- AND N-LINKED GLYCANS ON PROTEIN RECEPTOR
      • N-Linked Glycans
      • O-Linked Glycans
      • Glycosaminoglycans
      • Glycolipids
      • Glycosylphosphatidylinositol Anchors
    • FUNCTION OF GLYCANS AND THEIR BIOLOGICAL SIGNIFICANCE
      • Structural Role of Glycans
      • Glycans as Specific Ligands for Cell-Cell Interactions
      • Glycans as Specific Ligands for Cell-Microbe Interactions
        • TABLE 2: EXAMPLES OF GLYCOSYLATION DEFICIENCY AND THEIR PATHOLOGICAL EFFECT
    • RESEARCH TOOLS FOR GLYCOBIOLOGY STUDIES
      • TABLE 3: EXPERIMENTAL APPROACHES TO STUDYING GLYCANS
      • Glycan-Binding Proteins or Antibodies
      • Metabolic Inhibition or Alteration of Glycosylation
        • TABLE 4: EXAMPLES OF INHIBITORS/MODULATORS USED IN GLYCOBIOLOGY RESEARCH
      • Finding Natural Glycan Ligands for Specific Receptors
      • Finding Receptors for Specific Glycans
      • Competition Studies Using Soluble Glycans or Structural Mimics
      • Eliminating Specific Glycan Structures by Glycosidases
      • Studying Natural or Genetically Engineered Glycan Mutants
      • Studying Natural or Genetically Engineered Glycan Receptor Mutants
    • STRUCTURAL ANALYSIS OF GLYCANS
      • TABLE 5: SEPARATION AND IDENTIFICATION TECHNIQUES USED FOR GLYCAN ANALYSIS
      • Detection of Glycans
      • Release, Profiling and Fractionation of Glycans
    • GLYCOMICS AS PART OF GLYCOBIOLOGY RESEARCH
      • Mass Spectrometry
      • Lectin and Antibody Arrays
      • Cell and Tissue Analysis Using Lectins and Antibodies
      • Imaging the Glycome by Metabolic and Covalent Labeling
    • CHEMICAL AND ENZYMATIC SYNTHESIS OF GLYCANS AND GLYCOCONJUGATES
    • BIOINFORMATICS AND DATABASE RESOURCES FOR GLYCOBIOLOGY RESEARCH
      • TABLE 6: BIOINFORMATICS AND DATABASE RESOURCES FOR GLYCOBIOLOGY RESEARCH

CHAPTER 4 - GLYCOBIOLOGY THERAPEUTICS MARKET

  • OVERVIEW
  • SUBCATEGORIES OF GLYCOBIOLOGY THERAPEUTICS
  • GLYCANS AS COMPONENTS OF SMALL-MOLECULE DRUGS
    • TABLE 7: GLOBAL MARKET FOR SYSTEMIC ANTIBIOTICS, THROUGH 2020 ($ BILLIONS)
  • SMALL-MOLECULE INHIBITORS OF INFLUENZA VIRUS NEURAMINIDASE
    • TABLE 8: GLOBAL SALES OF RELENZA AND TAMIFLU, 2014 AND 2015 ($ MILLIONS)
  • THERAPEUTIC GLYCOPROTEINS
    • TABLE 9: GLOBAL SALES OF ARANESP, 2014 AND 2015 ($ MILLIONS)
  • GLYCAN THERAPEUTIC APPROACHES TO METABOLIC DISEASES
    • Salvage versus De Novo Synthesis
    • Special Diets
    • Substrate Reduction Therapy
      • TABLE 10: GLOBAL SALES OF ZAVESCA, 2014 AND 2015 ($ MILLIONS)
    • Lysosomal Enzyme Replacement Therapy
      • TABLE 11: GLOBAL SALES OF CEREZYME, NAGLAZYME AND ALDURAZYME, 2014 THROUGH MARCH 2016 ($ MILLIONS)
    • Chaperone Therapy
  • THERAPEUTIC APPLICATIONS OF GLYCOSAMINOGLYCANS
    • TABLE 12: GLOBAL SALES OF LOVENOX AND FRAGMIN, 2014 AND 2015 ($ MILLIONS)
  • CARBOHYDRATE-BASED VACCINES AND GLYCANS AS VACCINE COMPONENTS
    • TABLE 13: GLOBAL SALES OF PREVNAR 13, 2014 AND 2015 ($ MILLIONS)
  • BLOCKING GLYCAN RECOGNITION IN DISEASES
  • TRANSFUSION AND TRANSPLANTATION REJECTION BY ANTIGLYCAN ANTIBODIES
    • TABLE 14: EXAMPLES OF APPROVED GLYCOBIOLOGY-RELATED TREATMENTS AND CARBOHYDRATE-BASED DRUGS
    • TABLE 15: SALES OF GLUCOBAY, 2014 AND 2015 ($ MILLIONS)
  • GLYCOBIOLOGY THERAPEUTICS IN DEVELOPMENT
    • TABLE 16: EXAMPLES OF GLYCOBIOLOGY-RELATED TREATMENTS AND CARBOHYDRATE-BASED DRUGS IN DEVELOPMENT
    • Alectos Therapeutics
    • Amicus Therapeutics
    • Endotis Pharma
    • Galectin Therapeutics
    • Glixis Therapeutics
    • Glycan Biosciences
    • Glycan Therapeutics
    • GlycoGenesys
    • Glycomantra
    • Glycomar
    • GlycoMimetics
    • Glycomine
    • GlycoMira Therapeutics
    • Glycotope GmbH
    • Malcisbo AG
    • ProtAffin Biotechnologie AG
    • Siamab Therapeutics
    • VaxAlta
    • Vaxil Bio Therapeutics
  • EVALUATION OF GLYCOBIOLOGY THERAPEUTICS MARKET
    • OVERVIEW
      • Carbohydrate-Based Drugs
        • TABLE 17: EXAMPLES OF APPROVED CARBOHYDRATE-BASED DRUGS
      • Glycosylated Small Molecules
      • Glycoproteins as Therapeutics
      • Glycan Therapeutic Approaches to Metabolic Diseases
      • Blocking Glycan Recognition in Diseases
      • Carbohydrate-based Vaccines and Glycans as Vaccine
        • TABLE 18: GLOBAL MARKET FOR GLYCOBIOLOGY THERAPEUTICS, THROUGH 2021 ($ BILLIONS)
        • FIGURE 2: GLOBAL MARKET FOR GLYCOBIOLOGY THERAPEUTICS, 2014-2021 ($ BILLIONS)
    • MARKET LANDSCAPE
      • TABLE 19: EXAMPLES OF CARBOHYDRATE-BASED DRUGS APPROVED AS CANCER ADJUVANTS IN COUNTRIES OUTSIDE THE U.S.
      • TABLE 20: GEOGRAPHICAL DISTRIBUTION OF GLYCOBIOLOGY THERAPEUTIC MARKET, 2016 (%)
  • MARKET TRENDS IN GLYCOBIOLOGY THERAPEUTICS
    • PROTEIN AND GLYCAN GLYCOENGINEERING TO ENHANCE EFFICACY AND THERAPEUTIC VALUE
    • ENGINEERING GLYCANS AND GLYCAN MIMICS AS THERAPEUTIC AGENTS
      • Glycan Small Molecule Drugs
      • Polyvalent Glycan Structures and Inhibitors
    • GLYCOBIOLOGY AND DRUG DELIVERY
      • TABLE 21: GLOBAL MARKET FOR DRUG DELIVERY, THROUGH 2020 ($ BILLIONS)
    • OLIGOSACCHARIDE LIBRARIES FOR DRUG DISCOVERY RESEARCH
    • GLYCONUTRIENTS AS THERAPEUTICS
      • Glucosamine and Chondroitin Sulfate
      • Xylitol and Sorbitol in Chewing Gum
      • Milk Oligosaccharides
      • Chitosan
        • TABLE 22: GLOBAL MARKET FOR NUTRACEUTICALS, THROUGH 2019 ($ BILLIONS)

CHAPTER 5 - GLYCOBIOLOGY DIAGNOSTICS MARKET

  • OVERVIEW
    • GLYCOBIOMARKERS AND AUTOIMMUNITY
    • GLYCOBIOMARKERS IN INFLAMMATORY BOWEL DISEASE
    • AUTOANTIBODIES AGAINST NEURONAL GLYCANS IN CERTAIN NEUROPATHIES
    • AUTOANTIBODIES AGAINST TN ANTIGEN IN TN-POLYAGGLUTININ SYNDROME
    • GLYCOBIOLOGY MARKERS IN CARDIOVASCULAR DISEASES
    • ROLE OF GLYCANS IN THE HISTOPATHOLOGY OF ALZHEIMER'S DISEASE
    • GLYCOBIOMARKERS AND ASTHMA
    • GLYCOBIOMARKERS IN INFECTIOUS DISEASE TESTING
      • TABLE 23: EXAMPLES OF GLYCOBIOLOGY-BASED BIOMARKERS
    • MARKET POTENTIAL FOR GLYCOBIOLOGY-BASED BIOMARKERS AND DIAGNOSTIC TESTS
      • TABLE 24: CURRENT U.S. MARKET POTENTIAL FOR DIAGNOSTIC TESTS BASED ON GLYCOBIOLOGY BIOMARKERS (MILLIONS/$ MILLIONS)
    • GLYCOBIOLOGY-BASED CANCER BIOMARKERS AND DIAGNOSTIC DEVELOPMENT
      • TABLE 25: EXAMPLE OF GLOBAL CANCER STATISTICS, 2012
      • TABLE 26: FDA-APPROVED CANCER BIOMARKERS CURRENTLY USED IN CLINICAL PRACTICE
      • a-Fetoprotein (AFP)
      • Prostate-Specific Antigen (PSA)
      • MUC16 (CA125)
      • Human Epididymis Protein 4 (HE4)
      • MUC1 (CA15-3/CA27.29)
      • Human Epidermal Growth Factor Receptor 2 (HER2)
      • Carcinoembryonic Antigen (CEA)
      • Carbohydrate Antigen (CA19-9)
      • Thyroglobulin (Tg)
      • Potential Novel Biomarkers in Cancer Diagnostics
        • TABLE 27: EXAMPLES OF POTENTIAL GLYCOPROTEIN CANCER BIOMARKERS
        • Human Chorionic Gonadotropin (hCG)
        • Alpha-1-Antitrypsin (A1AT)
        • Fucosylated Haptoglobin (Fuc-Hpt)
        • YKL-40
      • Carbohydrates as Potential Serum Biomarkers
        • TABLE 28: EXAMPLES OF CLINICAL TRIALS USING BLOOD/PLASMA OR SERUM CARBOHYDRATE ANALYSIS TO DIAGNOSE AND MONITOR CANCER
        • TABLE 29: GLOBAL MARKET FOR TECHNOLOGIES FOR CANCER PROFILING AND PATHWAYS, THROUGH 2018 ($ BILLIONS)
  • CURRENT GLYCOBIOLOGY-BASED DIAGNOSTICS ON THE MARKET
    • GLUCOSE MONITORING FOR DIABETES
      • TABLE 30: GLOBAL MARKET FOR CONTINUOUS GLUCOSE MONITORING, THROUGH 2019 ($ MILLIONS)
    • GLYCOHEMOGLOBIN (HBA1C, A1C)
    • CARBOHYDRATE INTOLERANCE TEST
    • CARBOHYDRATE-DEFICIENT TRANSFERRIN (CDT)
      • TABLE 31: GLOBAL MARKET FOR DRUG TESTING, THROUGH 2019 ($ BILLIONS)
    • COMPANIES WITH GLYCOBIOLOGY DIAGNOSTIC PLATFORMS AND PRODUCTS IN DEVELOPMENT
      • TABLE 32: EXAMPLES OF COMPANIES WITH DIAGNOSTIC PRODUCTS IN DEVELOPMENT BASED ON GLYCOBIOLOGY RESEARCH
      • GENOS GLYKO
      • GLYCODIAG
      • GLYCOMARK
      • GLUCOSENSE DIAGNOSTICS
      • GLYCOSENSORS AND DIAGNOSTICS LLC
      • GLYCOTECHNICA LTD.
      • GLYCOTEST DIAGNOSTICS
      • SIGMA DIAGNOSTICS
    • MARKET FOR GLYCOBIOLOGY-BASED DIAGNOSTICS
      • TABLE 33: GLOBAL MARKET FOR CLINICAL BIOMARKERS USED IN METABOLOMICS, THROUGH 2020 ($ MILLIONS)
      • TABLE 34: GLOBAL MARKET FOR GLYCOBIOLOGY-BASED DIAGNOSTICS, THROUGH 2021 ($ BILLIONS)
      • FIGURE 3: GLOBAL MARKET FOR GLYCOBIOLOGY-BASED DIAGNOSTICS, 2014-2021 ($ BILLIONS)

CHAPTER 6 - MARKET FOR TOOLS AND REAGENTS USED IN GLYCOBIOLOGY RESEARCH AND DEVELOPMENT

  • OVERVIEW
    • ANALYTICAL AND CHROMATOGRAPHY TECHNIQUES
    • GLYCAN ARRAYS
    • LECTIN ARRAYS
    • GLYCOBIOLOGY KITS
    • REAGENTS FOR GLYCOBIOLOGY RESEARCH
    • CARBOHYDRATES: MONOSACCHARIDES, OLIGOSACCHARIDES AND OTHER REAGENTS
      • TABLE 35: EXAMPLES OF SUPPLIERS OF GLYCOBIOLOGY REAGENTS
      • Agilent Technologies
      • AMSBIO
      • Biognosys
      • CEVEC Pharmaceuticals GmbH
      • GALAB Technologies
      • Genos Glyco
      • GlycoBac LLC
      • Glycobiotech GmbH
      • Glykos Analytics
      • GlycoScientific LLC
      • GlycoSeLect Ltd.
      • Glycoseparations
      • GlycoTech
      • GlycoThera
      • IsoSep
      • LC Scientific Inc.
      • Ludger
      • New England Biolabs (NEB)
      • Omicron Biochemicals Inc.
      • Plexera
      • Prozyme
      • RayBiotech
      • R&D Systems
      • Robotic Labware Designs
      • Savyon Diagnostics
      • S-BIO
      • Sciex
      • Sigma-Aldrich
      • Sussex Research
      • Thermo Fisher Scientific
      • Vector Laboratories
      • Waters Corp.
        • TABLE 36: PRICES FOR GLYCOBIOLOGY REAGENTS AND SERVICES ($)
        • TABLE 37: GLOBAL MARKET FOR RESEARCH ASSAYS USED IN METABOLOMICS, THROUGH 2020 ($ MILLIONS)
    • MARKET FOR TOOLS AND REAGENTS FOR GLYCOBIOLOGY R&D
      • TABLE 38: EXAMPLES OF ANNUAL REVENUES OF COMPANIES THAT OFFER GLYCOBIOLOGY RESEARCH TOOLS ($ MILLIONS)
      • TABLE 39: GLOBAL MARKET FOR REAGENTS AND TOOLS FOR GLYCOBIOLOGY RESEARCH AND DEVELOPMENT, THROUGH 2021 ($ MILLIONS)
      • FIGURE 4: GLOBAL MARKET FOR REAGENTS AND TOOLS FOR GLYCOBIOLOGY RESEARCH AND DEVELOPMENT, 2014-2021 ($ MILLIONS)

CHAPTER 7 - PATENT ANALYSIS OF GLYCOBIOLOGY MARKET

  • OVERVIEW
    • TABLE 40: NUMBER OF U.S. PATENTS AND APPLICATIONS ON GLYCOBIOLOGY RESEARCH
    • TABLE 41: NUMBER OF U.S. PATENTS ON GLYCOBIOLOGY RESEARCH, 2012-2015
    • TABLE 42: EXAMPLES OF PATENTS FILED ON GLYCOBIOLOGY RESEARCH
    • TABLE 43: NUMBER OF PATENTS IN GLYCOBIOLOGY RESEARCH BY PATENT HOLDER, 2012-2015

CHAPTER 8 - MARKET SUMMARY

  • TABLE 44: GLOBAL MARKET FOR GLYCOBIOLOGY BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • FIGURE 5: GLOBAL MARKET FOR GLYCOBIOLOGY BY SEGMENT, 2014-2021 ($ MILLIONS)
  • TABLE 45: EXAMPLES OF MAIN MARKET PARTICIPANTS IN GLYCOBIOLOGY MARKET BY SEGMENT

CHAPTER 9 - OVERVIEW OF SELECT COMPANIES IN THE GLYCOBIOLOGY MARKET

  • BIOMARIN PHARMACEUTICAL INC.
  • GLYCOMIMETICS
  • GLYCAN BIOSCIENCES LLC
  • GLYCOSENSORS AND DIAGNOSTICS LLC
  • GLYCOTEST INC.

CHAPTER 10 - DIRECTORY OF COMPANIES REFERRED TO IN THE REPORT

  • DIRECTORY OF COMPANIES

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR GLYCOBIOLOGY, BY SEGMENT, THROUGH 2021 ($ MILLIONS) 7
    • TABLE 1: CLASSIFICATION OF CARBOHYDRATES 9
    • TABLE 2: EXAMPLES OF GLYCOSYLATION DEFICIENCY AND THEIR PATHOLOGICAL EFFECT 16
    • TABLE 3: EXPERIMENTAL APPROACHES TO STUDYING GLYCANS 18
    • TABLE 4: EXAMPLES OF INHIBITORS/MODULATORS USED IN GLYCOBIOLOGY RESEARCH 19
    • TABLE 5: SEPARATION AND IDENTIFICATION TECHNIQUES USED FOR GLYCAN ANALYSIS 22
    • TABLE 6: BIOINFORMATICS AND DATABASE RESOURCES FOR GLYCOBIOLOGY RESEARCH 28
    • TABLE 7: GLOBAL MARKET FOR SYSTEMIC ANTIBIOTICS, THROUGH 2020 ($ BILLIONS) 31
    • TABLE 8: GLOBAL SALES OF RELENZA AND TAMIFLU, 2014 AND 2015 ($ MILLIONS) 33
    • TABLE 9: GLOBAL SALES OF ARANESP, 2014 AND 2015 ($ MILLIONS) 34
    • TABLE 10: GLOBAL SALES OF ZAVESCA, 2014 AND 2015 ($ MILLIONS) 36
    • TABLE 11: GLOBAL SALES OF CEREZYME, NAGLAZYME AND ALDURAZYME, 2014 THROUGH MARCH 2016 ($ MILLIONS) 37
    • TABLE 12: GLOBAL SALES OF LOVENOX AND FRAGMIN, 2014 AND 2015 ($ MILLIONS) 39
    • TABLE 13: GLOBAL SALES OF PREVNAR 13, 2014 AND 2015 ($ MILLIONS) 40
    • TABLE 14: EXAMPLES OF APPROVED GLYCOBIOLOGY-RELATED TREATMENTS AND CARBOHYDRATE-BASED DRUGS 44
    • TABLE 15: SALES OF GLUCOBAY, 2014 AND 2015 ($ MILLIONS) 45
    • TABLE 16: EXAMPLES OF GLYCOBIOLOGY-RELATED TREATMENTS AND CARBOHYDRATE-BASED DRUGS IN DEVELOPMENT 45
    • TABLE 17: EXAMPLES OF APPROVED CARBOHYDRATE-BASED DRUGS 54
    • TABLE 18: GLOBAL MARKET FOR GLYCOBIOLOGY THERAPEUTICS, THROUGH 2021 ($ BILLIONS) 56
    • TABLE 19: EXAMPLES OF CARBOHYDRATE-BASED DRUGS APPROVED AS CANCER ADJUVANTS IN COUNTRIES OUTSIDE THE U.S. 57
    • TABLE 20: GEOGRAPHICAL DISTRIBUTION OF GLYCOBIOLOGY THERAPEUTIC MARKET, 2016 (%) 57
    • TABLE 21: GLOBAL MARKET FOR DRUG DELIVERY, THROUGH 2020 ($ BILLIONS) 64
    • TABLE 22: GLOBAL MARKET FOR NUTRACEUTICALS, THROUGH 2019 ($ BILLIONS) 67
    • TABLE 23: EXAMPLES OF GLYCOBIOLOGY-BASED BIOMARKERS 73
    • TABLE 24: CURRENT U.S. MARKET POTENTIAL FOR DIAGNOSTIC TESTS BASED ON GLYCOBIOLOGY BIOMARKERS (MILLIONS/$ MILLIONS) 74
    • TABLE 25: EXAMPLE OF GLOBAL CANCER STATISTICS, 2012 75
    • TABLE 26: FDA-APPROVED CANCER BIOMARKERS CURRENTLY USED IN CLINICAL PRACTICE 76
    • TABLE 27: EXAMPLES OF POTENTIAL GLYCOPROTEIN CANCER BIOMARKERS 81
    • TABLE 28: EXAMPLES OF CLINICAL TRIALS USING BLOOD/PLASMA OR SERUM CARBOHYDRATE ANALYSIS TO DIAGNOSE AND MONITOR CANCER 83
    • TABLE 29: GLOBAL MARKET FOR TECHNOLOGIES FOR CANCER PROFILING AND PATHWAYS, THROUGH 2018 ($ BILLIONS) 84
    • TABLE 30: GLOBAL MARKET FOR CONTINUOUS GLUCOSE MONITORING, THROUGH 2019 ($ MILLIONS) 85
    • TABLE 31: GLOBAL MARKET FOR DRUG TESTING, THROUGH 2019 ($ BILLIONS) 86
    • TABLE 32: EXAMPLES OF COMPANIES WITH DIAGNOSTIC PRODUCTS IN DEVELOPMENT BASED ON GLYCOBIOLOGY RESEARCH 87
    • TABLE 33: GLOBAL MARKET FOR CLINICAL BIOMARKERS USED IN METABOLOMICS, THROUGH 2020 ($ MILLIONS) 90
    • TABLE 34: GLOBAL MARKET FOR GLYCOBIOLOGY-BASED DIAGNOSTICS, THROUGH 2021 ($ BILLIONS) 91
    • TABLE 35: EXAMPLES OF SUPPLIERS OF GLYCOBIOLOGY REAGENTS 103
    • TABLE 36: PRICES FOR GLYCOBIOLOGY REAGENTS AND SERVICES ($) 115
    • TABLE 37: GLOBAL MARKET FOR RESEARCH ASSAYS USED IN METABOLOMICS, THROUGH 2020 ($ MILLIONS) 115
    • TABLE 38: EXAMPLES OF ANNUAL REVENUES OF COMPANIES THAT OFFER GLYCOBIOLOGY RESEARCH TOOLS ($ MILLIONS) 116
    • TABLE 39: GLOBAL MARKET FOR REAGENTS AND TOOLS FOR GLYCOBIOLOGY RESEARCH AND DEVELOPMENT, THROUGH 2021 ($ MILLIONS) 117
    • TABLE 40: NUMBER OF U.S. PATENTS AND APPLICATIONS ON GLYCOBIOLOGY RESEARCH 119
    • TABLE 41: NUMBER OF U.S. PATENTS ON GLYCOBIOLOGY RESEARCH, 2012-2015 119
    • TABLE 42: EXAMPLES OF PATENTS FILED ON GLYCOBIOLOGY RESEARCH 120
    • TABLE 43: NUMBER OF PATENTS IN GLYCOBIOLOGY RESEARCH BY PATENT HOLDER, 2012-2015 124
    • TABLE 44: GLOBAL MARKET FOR GLYCOBIOLOGY BY SEGMENT, THROUGH 2021 ($ MILLIONS) 128
    • TABLE 45: EXAMPLES OF MAIN MARKET PARTICIPANTS IN GLYCOBIOLOGY MARKET BY SEGMENT 129

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET FOR GLYCOBIOLOGY, BY SEGMENT, 2014-2021 ($ MILLIONS) 7
    • FIGURE 1: SCHEMATIC PRESENTATION OF O- AND N-LINKED GLYCANS ON PROTEIN RECEPTOR 11
    • FIGURE 2: GLOBAL MARKET FOR GLYCOBIOLOGY THERAPEUTICS, 2014-2021 ($ BILLIONS) 56
    • FIGURE 3: GLOBAL MARKET FOR GLYCOBIOLOGY-BASED DIAGNOSTICS, 2014-2021 ($ BILLIONS) 92
    • FIGURE 4: GLOBAL MARKET FOR REAGENTS AND TOOLS FOR GLYCOBIOLOGY RESEARCH AND DEVELOPMENT, 2014-2021 ($ MILLIONS) 117
    • FIGURE 5: GLOBAL MARKET FOR GLYCOBIOLOGY BY SEGMENT, 2014-2021 ($ MILLIONS) 129
Back to Top